Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919796 · ClinicalTrials.gov registry record · Phase 2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
A Phase 2 study, sponsored by PharmaJet.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT06919796 is a Phase 2 study that has not yet begun recruiting, run by PharmaJet. The registered enrollment target is 40 participants.
The verdict
NCT06919796, a Phase 2 study, has not yet begun recruiting, sponsored by PharmaJet.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe
Interventions
- BIOLOGICAL COMIRNATY®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06919796
The ClinicalTrials.gov registry entry for NCT06919796 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaJet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COMIRNATY® is the first listed.
NCT06919796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06919796 about?
NCT06919796 is a clinical study titled "mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes". The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe
What is the current status of trial NCT06919796?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-01. Estimated completion is 2026-11-25.
What interventions are being tested in trial NCT06919796?
The interventions under investigation include: COMIRNATY® (BIOLOGICAL).
Who is sponsoring clinical trial NCT06919796?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.